Inhibiting antibodies of ADAM10/17, CAECAM, or TIM-3, neutralizing sTIM-3, may reinvigorate the T cell response, particularly in anti-PD-1-resistant tumor patients.40 The gene discussed is HAVCR2; the disease is neoplasm.